Aripiprazole in autism spectrum disorders and fragile X syndrome (Q34025492)

30 July 2017

1 reference

title

Aripiprazole in autism spectrum disorders and fragile X syndrome (English)

1 reference

30 July 2017

autism spectrum disorder

0 references

0 references

1 reference

Christopher J McDougle

series ordinal

4

object named as

Christopher J McDougle

1 reference

30 July 2017

3

David J Posey

1 reference

30 July 2017

2

Kimberly A Stigler

1 reference

30 July 2017

Craig A Erickson

1

1 reference

30 July 2017

1 July 2010

1 reference

30 July 2017

1 reference

30 July 2017

7

1 reference

30 July 2017

258-263

1 reference

30 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1016/j.nurt.2010.04.001

30 July 2017

0 references

cites work

Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Advances in the treatment of fragile X syndrome

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Pharmacologic treatment of autism and related disorders

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Neurochemistry in the pathophysiology of autism.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Aripiprazole for maladaptive behavior in pervasive developmental disorders

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Psychopharmacology in fragile X syndrome--present and future

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Risperidone in children with autism and serious behavioral problems

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Strategy for modulation of central dopamine transmission based on the partial agonist concept in schizophrenia therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

Prevalence of parent-reported diagnosis of autism spectrum disorder among children in the US, 2007.

5 July 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Autistic behavior, FMR1 protein, and developmental trajectories in young males with fragile X syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Amygdala dysfunction in men with the fragile X premutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Effects of short- and long-term risperidone treatment on prolactin levels in children with autism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2010.04.001

Neurobehavioral phenotype in carriers of the fragile X premutation

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2911359

10.1016/J.NURT.2010.04.001

29 October 2018

Identifiers

DOI

1 reference

PubMed ID

20643378

Dimensions Publication ID

30 July 2017

0 references

1 reference

30 July 2017

1 reference

PubMed ID

20643378